Table 1 Overview of the diagnostic accuracy of the αSyn RT-QuIC assay in different studies
From: α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies
Reference | Source | Substrate | Accuracy indicated by sensitivity and specificity |
|---|---|---|---|
Fairfoul et al. [43] | CSF | Hu FL αSyn | 92%–95% sensitivity and 100% specificity for DLB and PD versus AD and controls; DLB (n = 12), PD (n = 22), AD (n = 30), mixed DLB/AD (n = 17), HC (n = 20), PD control (n = 15) |
Saijo et al. [47] | CSF | His-WT, K23Q αSyn | 92% sensitivity and 100% specificity for PD and DLB |
Groveman et al. [46] | CSF | K23Q αSyn | 93% sensitivity and 100% specificity; DLB (n = 17), PD (n = 12), AD (n = 16), non-α-synucleinopathy controls (n = 31) |
Bongianni et al. [48] | CSF | Hu FL αSyn | 92.9% sensitivity and 95.9% specificity synucleinopathies versus non‐α-synucleinopathy; αSyn (n = 27), non-αSyn (n = 49) |
Garrido et al. [49] | CSF | Hu FL αSyn | 40% LRRK2‐PD and 18.8% LRRK2‐NMC with positive RT-QuIC results; IPD with 90% sensitivity and 80% specificity LRRK2-PD (n = 15), LRRK2-NMC (n = 16), IPD (n = 10), HC (n = 10) |
Manne et al. [44] | CSF | Hu FL αSyn | 100% sensitivity and specificity; PD (n = 15) compared with controls (n = 11) |
van Rumund et al. [50] | CSF | Hu FL αSyn | 75% sensitivity and 85%–98% specificity; αSyn (n = 85), non-αSyn (n = 26) |
Rossi et al. [51] | CSF | Hu FL αSyn | 98% specificity and 95.3% sensitivity for α-synucleinopathies (DLB + PD + iRBD + PAF); LB-αSyn + (n = 21), LB-αSyn − (n = 101) |
Shahnawaz et al. [52] | CSF | Hu FL αSyn | 95.4% sensitivity to discriminate PD and MSA; n = 153 |
Orrú et al. [53] | CSF | K23Q αSyn | 97% sensitivity and 87% specificity for PD versus controls PD (n = 108), HC (n = 85) |
Bargar et al. [54] | CSF | Hu FL αSyn | 98% sensitivity and 100% specificity PD (n = 88), DLB (n = 58), Controls (n = 68) |
Rossi et al. [55] | CSF | Hu FL αSyn | 95% sensitivity and 97% specificity for MCI-LB patients versus controls |
Donadio et al. [56] | CSF | Hu FL αSyn | 78% sensitivity and 100% specificity for α-synucleinopathies versus controls; α-synucleinopathies (n = 9), non-α-synucleinopathies (n = 24), controls (n = 16) |
Manne et al. [57] | Skin | Hu FL αSyn | PD versus control: 96% sensitivity and 96% specificity for frozen skin tissues (PD n = 25, control n = 25); 75% sensitivity and 83% specificity for formalin-fixed paraffin-embedded skin sections (PD n = 12, control n = 12) |
Wang et al., 2020 [58] | Skin | Hu FL αSyn | 93% sensitivity and 93% specificity for synucleinopathies (PD, DLB, MSA) versus controls (AD, PSP, CBD, NNCs.); α-synucleinopathies (n = 57), controls (n = 73) |
Mammana et al. [59] | Skin | K23Q αSyn | 89.2% sensitivity and 96.3% specificity for DLB versus neurological controls; vitam (n = 69), post-mortem (n = 49) |
Donadio et al. [56] | Skin | Hu FL αSyn | 86% sensitivity and 80% specificity; α-synucleinopathies (n = 31), non-α-synucleinopathies (n = 38), controls (n = 24) |
Stefani et al. [60] | OM | Hu FL αSyn | 45.2% sensitivity and 89.9% specificity for RBD plus PD versus controls |
Manne et al. [61] | SMG | Hu FL αSyn | 100% sensitivity and 94% specificity; PD (n = 13), ILBD (n = 3), controls (n = 16) |